Abstract
Resistant hypertension is prevalent throughout the world and depending on the definition affects 3–10 % of people with hypertension. A large percentage of patients do not meet guideline blood pressure goals, and this number very well may increase with the results from the recent Systolic Blood Pressure Intervention Trial (SPRINT) demonstrating significantly improved mortality at lower blood pressure levels. Uncontrolled hypertension, i.e., a BP > 140/90 mmHg, increases cardiovascular morbidity and mortality and results in the progression of chronic kidney disease. An inability to adequately control blood pressure among patients who are adherent to medications is multifactorial. A major contributing factor, besides inadequate diuretic therapy, is the failure of pharmacotherapy to effectively inhibit the sympathetic nervous system. Moreover, most drugs targeting the sympathetic nervous system are not particularly well tolerated. Consequently, device-driven approaches are being developed and tested. Carotid baroreceptor stimulation is one such approach.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Abbreviations
- BAT:
-
Baroreceptor activation therapy
- BP:
-
Blood pressure
- CBS:
-
Carotid baroreceptor stimulation
- HTN:
-
Hypertension
- SNS:
-
Sympathetic nervous system
References
Egan BM, Zhao Y, Axon RN (2010) US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008. JAMA 303(20):2043–2050
James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J et al (2014) 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 311(5):507–520
Acelajado MC, Pisoni R, Dudenbostel T, Dell’Italia LJ, Cartmill F, Zhang B et al (2012) Refractory hypertension: definition, prevalence, and patient characteristics. J Clin Hypertens 14(1):7–12
Group SR, Wright JT Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM et al (2015) A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 373(22):2103–2116
Taler SJ (2005) Treatment of resistant hypertension. Curr Hypertens Rep 7(5):323–329
Briasoulis A, Bakris GL (2012) Timing and efficacy of alternative methods of sympathetic blockade. Curr Hypertens Rep 14(5):455–461
Bhatt DL, Kandzari DE, O’Neill WW, D’Agostino R, Flack JM, Katzen BT et al (2014) A controlled trial of renal denervation for resistant hypertension. N Engl J Med 370(15):1393–1401
Mahfoud F, Tunev S, Ewen S, Cremers B, Ruwart J, Schulz-Jander D et al (2015) Impact of lesion placement on efficacy and safety of catheter-based radiofrequency renal denervation. J Am Coll Cardiol 66(16):1766–1775
Kandzari DE, Kario K, Mahfoud F, Cohen SA, Pilcher G, Pocock S et al (2016) The SPYRAL HTN Global Clinical Trial Program: rationale and design for studies of renal denervation in the absence (SPYRAL HTN OFF-MED) and presence (SPYRAL HTN ON-MED) of antihypertensive medications. Am Heart J 171(1):82–91
Abboud FM (1979) Integration of reflex responses in the control of blood pressure and vascular resistance. Am J Cardiol 44(5):903–911
Goldstein DS (1983) Plasma catecholamines and essential hypertension. An analytical review. Hypertension 5(1):86–99
Grassi G, Cattaneo BM, Seravalle G, Lanfranchi A, Mancia G (1998) Baroreflex control of sympathetic nerve activity in essential and secondary hypertension. Hypertension 31(1):68–72
Grassi G, Seravalle G, Quarti-Trevano F, Scopelliti F, Dell’Oro R, Bolla G et al (2007) Excessive sympathetic activation in heart failure with obesity and metabolic syndrome: characteristics and mechanisms. Hypertension 49(3):535–541
Lohmeier TE, Hildebrandt DA, Warren S, May PJ, Cunningham JT (2005) Recent insights into the interactions between the baroreflex and the kidneys in hypertension. Am J Physiol Regul Integr Comp Physiol 288(4):R828–R836
Carlsten A, Folkow B, Grimby G, Hamberger CA, Thulesius O (1958) Cardiovascular effects of direct stimulation of the carotid sinus nerve in man. Acta Physiol Scand 44(2):138–145
Scheffers IJ, Kroon AA, de Leeuw PW (2010) Carotid baroreflex activation: past, present, and future. Curr Hypertens Rep 12(2):61–66
Victor RG (2015) Carotid baroreflex activation therapy for resistant hypertension. Nat Rev Cardiol 12(8):451–463
Bakris GL, Nadim MK, Haller H, Lovett EG, Schafer JE, Bisognano JD (2012) Baroreflex activation therapy provides durable benefit in patients with resistant hypertension: results of long-term follow-up in the Rheos Pivotal Trial. J Am Soc Hypertens 6(2):152–158
Bisognano JD, Bakris G, Nadim MK, Sanchez L, Kroon AA, Schafer J et al (2011) Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebo-controlled Rheos Pivotal Trial. J Am Coll Cardiol 58(7):765–773
Scheffers IJ, Kroon AA, Schmidli J, Jordan J, Tordoir JJ, Mohaupt MG et al (2010) Novel baroreflex activation therapy in resistant hypertension: results of a European multi-center feasibility study. J Am Coll Cardiol 56(15):1254–1258
Lovett EG, Schafer J, Kaufman CL (2009) Chronic baroreflex activation by the Rheos system: an overview of results from European and North American feasibility studies. Conf Proc IEEE Eng Med Biol Soc 2009:4626–4630
Hoppe UC, Brandt MC, Wachter R, Beige J, Rump LC, Kroon AA et al (2012) Minimally invasive system for baroreflex activation therapy chronically lowers blood pressure with pacemaker-like safety profile: results from the Barostim neo trial. J Am Soc Hypertens 6(4):270–276
Tordoir JH, Scheffers I, Schmidli J, Savolainen H, Liebeskind U, Hansky B et al (2007) An implantable carotid sinus baroreflex activating system: surgical technique and short-term outcome from a multi-center feasibility trial for the treatment of resistant hypertension. Eur J Vasc Endovasc Surg 33(4):414–421
Laffin LJ, Bakris GL (2015) Hypertension and new treatment approaches targeting the sympathetic nervous system. Curr Opin Pharmacol 21:20–24
de Leeuw PW, Alnima T, Lovett E, Sica D, Bisognano J, Haller H et al (2015) Bilateral or unilateral stimulation for baroreflex activation therapy. Hypertension 65(1):187–192
Iliescu R, Tudorancea I, Lohmeier TE (2014) Baroreflex activation: from mechanisms to therapy for cardiovascular disease. Curr Hypertens Rep 16(8):453
Halbach M, Hickethier T, Madershahian N, Reuter H, Brandt MC, Hoppe UC et al (2015) Acute on/off effects and chronic blood pressure reduction after long-term baroreflex activation therapy in resistant hypertension. J Hypertens 33(8):1697–1703
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Laffin, L.J., Bakris, G.L. (2016). Carotid Baroreceptor Stimulation. In: Tsioufis, C., Schmieder, R., Mancia, G. (eds) Interventional Therapies for Secondary and Essential Hypertension. Updates in Hypertension and Cardiovascular Protection. Springer, Cham. https://doi.org/10.1007/978-3-319-34141-5_22
Download citation
DOI: https://doi.org/10.1007/978-3-319-34141-5_22
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-34140-8
Online ISBN: 978-3-319-34141-5
eBook Packages: MedicineMedicine (R0)